An interventional study of Biologic Therapy in Asthma; Eosinophilic, sponsored by Western University, Canada. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Western University, Canada · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in this response? While about 4.6 million Canadians live with asthma, \~5-10% of patients have severe asthma meaning that multiple inhaled and systemic oral corticosteroid treatments have failed to improve symptoms and exacerbations, leading to lost work and school days and substantially diminished ability to participate in normal life. For such people, the vast majority of whom are middle aged and remember asthma as part of their entire lifespan, biologic immunomodulator therapies, which block the function of asthma inflammatory pathways, provide a final step-up therapy option. There is emerging evidence that prescribed in the right patient at the right time, the right biologic can result in clinical remission of asthma. While spontaneous clinical remission of asthma is rare, it has been documented in children in whom lung growth and remodeling is still possible. It remains unknown whether clinical remission in adults is accompanied by the reversal of pathologic remodeling, at the level of the airways and pulmonary vessels. This is critical to elucidate as investigators and physicians move forward with currently proposed criteria for "complete asthma remission". The inconvenient truth about asthma and age is that in older adult lungs, exposed to years of infection, exacerbations, smooth muscle remodeling and pulmonary vascular shunt, the mechanisms by which complete pathologic remission may be achieved are complex and poorly understood.
To address this knowledge gap, the investigators will evaluate 150 patients (Vancouver, Ottawa, Hamilton, London) (in three age tertiles 18-29; 30-59; 60-80) with severe asthma and 50 age- and sex matched healthy volunteers over 2-years using chest CT, MRI and pulmonary function tests. The investigators will use the pulmonary imaging measurements to generate an imaging-index of normal airway structure and function which will be compared with and significantly correlate with MR-guided bronchoscopic sample measurements made before and after 1-/2-years of treatment. The investigators will reveal the pathobiologic relationship between age, asthma duration, clinical remission and imaging normalization with direct comparison to histology-based airway measurements.
28 studies on the registry are indexed under Airway Remodeling; 5 are open to participants now.
This study's planned enrollment of 200 is above the median of 40 across 21 interventional studies indexed under Airway Remodeling.
Browse Airway Remodeling studies →Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants eligible for inclusion in this study must meet all the following criteria:
Women of (after menarche) must ensure that they are using an effective form of for at least 2 months prior to each imaging visit. Examples of effective birth control include:
Exclusion Criteria:
Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
Biological: Biologic Therapy
Age- and sex-matched healthy participants with no history of lung disease. Participants will undergo pulmonary imaging (CT, MRI) and lung function testing at baseline and follow-up for comparison with the asthma group. No therapeutic intervention will be provided.
Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
Determine extent of imaging-based remission in patients with severe asthma following 1 and 2 years of biologic therapy
Measured using 129Xe ventilation defect percent (VDP)
Time frame: from baseline to year 1 and year 2
Measure the extent and timing of clinical remission in patients with severe asthma as measured by changes in spirometry measurements of FEV1 and FVC
Measured using forced expiratory volume in 1 second and forced vital capacity
Time frame: from baseline to 1 year and 2 years
To determine the extent and timing of clinical remission in patients with severe asthma using symptoms scores of ACQ-5 and ACT
Measured using changes in asthma control questionnaire and asthma control test
Time frame: From baseline to 1 year and 2 years
Determine the extent and timing of imaging-based remission in patients with severe asthma using CT airway and vessel morphology
Measured using computed tomography (CT) airway and vessel metrics
Time frame: From baseline to 1 year and 2 years
To determine the extent and timing of clinical remission using the clinical outcome of frequency of asthma exacerbations in patients with severe asthma
Measured using the number of asthma exacerbations
Time frame: from baseline to 1 year and 2 years
To determine the extent and timing of clinical remission of patients with severe asthma using the clinical outcome of OCS use
Measured by the frequency of oral corticosteroid usage
Time frame: From baseline to 1 year and 2 years
Determine the extent and timing of clinical remission in patients with severe asthma as measured by sputum and blood eosinophil counts
Measured using blood and sputum eosinophil counts
Time frame: From baseline to 1 year and 2 years
Timing and proportion of patients achieving clinical remission after biologic treatment as measured by FEV1 and FVC.
Measured using forced expiratory volume at 1 second and forced vital capacity.
Time frame: From baseline to 1 year and 2 years
To determine the timing and proportion of patients achieving clinical remission as measured by ACQ-5 and ACT questionnaires.
Measured by asthma control questionnaire and asthma control test questionnaire scores.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using FeNO.
Measured using fractional exhaled nitric oxide (FeNO)
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission using DLco.
Measured using diffusing capacity of the lung for carbon monoxide (DLco)
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving clinical remission after biologic treatment using SGRQ score.
Measured using St. George's Respiratory Questionnaire (SGRQ) score.
Time frame: From baseline to 1 year and 2 years.
Determine the timing and proportion of patients with severe asthma achieving clinical remission on biologic treatment using AQLQ scores.
Measured using the Asthma Quality of Life Questionnaire (AQLQ) score.
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using 129-Xe MRI VDP
Measured using the changes in 129-xenon MRI ventilation defect percent (VDP)
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using CT metrics
Measured using computed tomography (CT) mucus-score, airway dimensions and vascular pruning
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using DLco.
Measured using diffusing capacity of the lung for carbon monoxide (DLco)
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using RV/TLC
Measured using the ratio of residual volume to total lung capacity (RV/TLC)
Time frame: From baseline to 1 year and 2 years
Determine the timing and proportion of patients with severe asthma achieving imaging normalization after biologic treatment using FRC.
Measured using functional residual capacity (FRC).
Time frame: From baseline to 1 year and 2 years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using changes in VDP
Measured using ventilation defect percent (VDP)
Time frame: from baseline to 12-weeks and 2-years
Determine the relationship between clinical and imaging remission and generate predictive models for their achievement using changes in CT.
Measured using computed tomography (CT) airway wall thickness, mucus metrics
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using FeNO.
Measured using forced exhaled nitric oxide (FeNO).
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using ACQ-5 and ACT scores.
Measured using asthma control questionnaire and asthma control test scores.
Time frame: From baseline to 12-weeks and 2-years.
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using sputum biomarkers.
Measured using sputum eosinophil and cell count values
Time frame: From baseline to 12-weeks and 2-years
Determine the relationships between clinical and imaging remission and generate predictive models for their achievement using exacerbation history.
Measured using patient's reported exacerbation history.
Time frame: From baseline to 12-weeks and 2-years.
Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization.
Measured using bronchoscopic airway histology (epithelial thickness, smooth muscle mass, vascularity).
Time frame: From baseline (Day 0) to year 2
Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization using MRI/CT correlations with histologic changes
Measured using MRI, CT and histology values
Time frame: From baseline to 2 years.
Quantify the relationships of imaging and pathologic markers of remodeling and develop a non-invasive imaging-index lung normalization using MRI/CT fusion data
Measured using MRI and CT measurements
Time frame: From baseline to 2 years.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.